Blog - Page 3 of 5747 - QualityStocks

ThursdaySep 24, 2026 3:24 pm

QualityStocksNewsBreaks – Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) Completes 2026 Field Exploration Program at Cameron Project

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising. Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF) has completed its 2026 field exploration program at the approximately 2,984-hectare Cameron Rare Earth Element Project in British Columbia, collecting 250 rock-chip, soil and stream-sediment samples that are now undergoing laboratory analysis. The campaign was designed to refine previously identified rare-earth-element (“REE”) geochemical anomalies, improve geological understanding and identify potential bedrock source areas for further exploration. Field observations included gneissic and granodioritic rocks, quartzite, pegmatitic material and quartz-veined zones. The pending assay results will provide the next key dataset for evaluating…

ThursdaySep 24, 2026 2:26 pm

QualityStocksNewsBreaks – Wrap Technologies Inc. (NASDAQ: WRAP) Expands Public Safety Strategy Beyond Law Enforcement

Wrap Technologies (NASDAQ: WRAP) is broadening its public safety strategy by combining training, situational awareness, technology and response capabilities into a more integrated platform designed for multiple professional markets. WRAP’s training methodologies—focused on threat recognition, situational awareness, early intervention and de-escalation—can extend beyond traditional law enforcement. The company is also developing Wrap Tactics, a digital learning management system intended to support scalable training, certification, recurring education and proficiency tracking. Alongside its WrapShield architecture and expansion into private security and other markets, WRAP is positioning training as a connecting layer between personnel and its public safety technologies, with potential applications across…

ThursdaySep 24, 2026 1:51 pm

QualityStocksNewsBreaks – HWAL Inc. (HWAL) Brings Music Royalties to the Tokenized RWA Market

HWAL (OTCID: HWAL) is pursuing a tokenized approach to music royalties as the broader real-world asset market expands, aiming to make royalty ownership and distribution more transparent and accessible through blockchain-based structures. Through its 50%-owned Lunar Records venture, the company formed Lunar Records Fund 1 in January 2026, a proposed $10 million fund built around Bitcoin-based $1 tokens that would provide holders with monthly distributions tied to royalties from 1,000 songs. HWAL says it could eventually expand the model to as much as $500 million in assets under management. Beyond streaming royalties, the company is seeking additional licensing opportunities for…

ThursdaySep 24, 2026 12:40 pm

QualityStocksNewsBreaks – Streamex Corp. (NASDAQ: STEX) Announces $1 Million Institutional Allocation to GLDY-Based Investment Strategy

Streamex (NASDAQ: STEX) announced that an institutional investment manager has launched an investment strategy using GLDY, the company’s gold-backed, yield-bearing tokenized asset, as the long leg of a gold-denominated delta-neutral trade. A leading institutional investor will allocate an initial $1 million to the strategy, with the potential for follow-on investments as the strategy demonstrates its performance. Streamex said it views strategies of this kind as a new channel for growing GLDY assets under management. Streamex also reported progress on the 90-day commitments outlined with its second-quarter earnings in August, including meeting its objectives of converting institutional allocations into GLDY and…

ThursdaySep 24, 2026 12:32 pm

QualityStocksNewsBreaks – Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) Subsidiary MindWave Signs 12-Month Technology Services Agreement with AQUAE Holdings

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) subsidiary MindWave Innovations Inc. signed a 12-month technology services agreement with Singapore-based AQUAE Holdings Pte. Ltd. to deploy its MindChain infrastructure as the foundation of AQUAEChain, a platform for insured ALCI Credits. MindWave will design, develop, deploy and host AQUAEChain, which will manage the issuance, verification, tracking, transfer and retirement of ALCI Credits, and will provide ongoing technical support. MindWave will receive contracted software development and technology service fees, while the agreement also references an allocation to MindWave equal to 20% of total ALCI Credits issued and outstanding on the AQUAEChain network, calculated…

ThursdaySep 24, 2026 12:12 pm

QualityStocksNewsBreaks – Greenland Mines Ltd (NASDAQ: GRML) President Discusses Critical Minerals Strategy, Project Development on MiningNewsWire Podcast

Greenland Mines (NASDAQ: GRML) President Dr. Bo Møller Stensgaard joined the latest episode of The MiningNewsWire Podcast to discuss the company’s North Atlantic critical minerals strategy, leadership team and development plans for its Greenland project portfolio. Stensgaard highlighted the Skaergaard Project, which is dominated by gold and palladium, and the Sarfartoq Project, which is focused on neodymium and praseodymium. Stensgaard also discussed Greenland Mines’ cross-border management and technical team and upcoming permitting and development milestones. He said Sarfartoq could cover one-third of Western production of neodymium and praseodymium over a nine-year mine life and described Skaergaard as a large palladium…

ThursdaySep 24, 2026 11:51 am

QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Advances Oncology Pipeline Following Nasdaq Listing as Xlife Sciences (SIX: XLS) Reports First-Half Progress

VERAXA Biotech (NASDAQ: VRXA) is shifting its focus to advancing its oncology pipeline and implementing industrial partnerships for its technology platforms and products following the completion of its business combination and commencement of Nasdaq trading in June 2026. Xlife Sciences AG (SIX: XLS) said VERAXA secured a financing base to support its next development steps and remains an important part of its portfolio strategy. Xlife Sciences also reported operational and scientific progress across its portfolio during the first half of 2026, including developments at x-kidney diagnostics, saniva diagnostics, Axenoll, FUSE-AI and inflamed pharma. The portfolio comprises 416 patents and patent…

ThursdaySep 24, 2026 11:43 am

QualityStocksNewsBreaks – BOXABL Inc. (NASDAQ: BXBL) Appoints Timothy Goldsmith to Board, Names Him Audit Committee Chair

BOXABL (NASDAQ: BXBL) announced the expansion of its board of directors and the appointment of Timothy Goldsmith, CPA, effective Sept. 24, 2026. Goldsmith will chair the Audit Committee and serve on the Nominating and Corporate Governance Committee. Dr. Morris A. Davis, the former Audit Committee chair, will remain a committee member. Goldsmith spent nearly 21 years at EY, most recently serving as an audit partner from 2018 to 2026. His experience includes public and private company audits, U.S. GAAP, IFRS, SEC and PCAOB standards and Sarbanes-Oxley compliance. BOXABL said the appointment follows the recent additions of Larry King as chief…

ThursdaySep 24, 2026 11:15 am

SS Innovations International Inc. (NASDAQ: SSII) Expands Robotic Cardiac Surgery Footprint with New Program at HCG Hospital in Ahmedabad

The program began with a robotic left internal mammary artery (“LIMA”) take-down performed by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, using the SSi Mantra advanced robotic surgical system from SS Innovations. SS Innovations reported 238 SSi Mantra systems installed as of September 8, up 42% from the end of 2025. The system is now installed across 12 countries, with recent expansion into Colombia, Sri Lanka and the Philippines. SS Innovations is pursuing U.S. FDA review and European Union CE marking as it seeks to expand SSi Mantra into additional international markets. SS Innovations International (NASDAQ: SSII), a…

ThursdaySep 24, 2026 10:30 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing

The FDA IND approval marks a pivotal step for the company's lead compound, known as Lucid-MS. What sets Quantum BioPharma’s proprietary treatment apart from most existing MS therapies is its mechanism. Lucid-MS previously completed phase 1 clinical trials, showing a favorable safety profile and being well tolerated. A green light from the U.S. Food and Drug Administration (“FDA”) can turn years of laboratory work into a real shot at treating patients, and that is exactly what just happened for one biopharmaceutical company. Quantum BioPharma (NASDAQ: QNTM), a company focused on neurodegenerative and metabolic disorders, announced that the FDA has approved…

Site Search

Company Search